Atopic Dermatitis

The study also found lasting benefits of the supplement for bone density up to age 4.

Pregnant women with atopic dermatitis and psoriasis may require special treatment considerations.

A pediatric dermatologist and pediatric allergist translated guidelines into clinical practice at AAD 2023.

Results from the phase 3 study were presented at an AAD late-breaking research session.

This question drummed up discussion during one AAD 2023 session on the topic. We want to hear from you!

With the recent therapeutic revolution, there has never been a better time to find the right treatment option for your patient suffering from inflammatory diseases.

An AAD 2023 poster presentation reviewed the long-term safety periods of the TruE-AD1 and TRuE-AD2 trials.

Atopic Dermatitis treatment and management options are explored at several sessions conducted by Peter Lio, MD, FAAD, at AAD 2023.

The latest phase 3 trial results were showcased in an AAD late-breaking research session.

Can dietary modifications really improve dermatological conditions?

Dermavant’s ADORING 2 phase 3 trial met all primary and secondary endpoints.

Treatment safety and efficacy for atopic dermatitis has seen significant growth over the last decade.

Researchers reviewed nearly 7 years' worth of patch testing data to analyze trends in hand eczema in Latin America.

A group of dermatologists and dermatology students studied why AD may be related to certain cardiovascular diseases, neuropsychiatric diseases, autoimmune diseases, and obesity.

To date, publications about health care disparities in atopic dermatitis in Latin American countries are few and far between.

Investigators compared these outcomes due to limited research in the space, with previous surveys suggesting care disparities.

Researchers link proximity to heavy traffic and risk of atopic dermatitis in new study.

Patients suffering from atopic dermatitis may suffer more during the cold, dry winter month. Bernard Cohen, MD, professor of pediatrics and dermatology at Johns Hopkins University School of Medicine in Baltimore, Maryland, explores various treatment options that will add moisture back into the skin during seasonal flare-ups.

Adolescents and adults with seborrheic dermatitis may have a new topical treatment soon.

Research published in JAMA Dermatology finds dupilumab works quickly and safely for patients with erythrodermic atopic dermatitis.

Alexis shares take-home points from his popular sessions at South Beach Symposium.

Matt Zirwas, MD, shares tips on diagnosing various forms of hand dermatitis and what patients can do to relieve symptoms of dermatitis at Maui Derm Hawaii 2023.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the design of the LIBERTY-AD open-label extension trial and share clinical context regarding safety findings.

Thought leaders share strategies for talking to patients about the importance of treatment adherence in the long-term management of atopic dermatitis.

Recommendations were made for patients to help relieve inflammation, itching and infections.

JAK inhibitors may cause less adverse events compared with traditional systemic therapies.

In part 5 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, evaluate the effect of the rapidly changing therapeutic landscape in atopic dermatitis.

Results from the test reveal that high levels of the immune biomarker Thymus and Activation-Regulated Chemokine (TARC) in babies increases their chances of developing atopic dermatitis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the burden of atopic dermatitis and discuss how they talk to patients about the impact their disease has on their lives.